What is Profusa?
Profusa, Inc. operates at the intersection of biotechnology and advanced engineering, specializing in the creation of biosensors that integrate seamlessly with human tissue. The company's flagship innovation, the Lumee Oxygen Platform, has achieved regulatory recognition with a CE Mark, enabling its deployment across the European Union. By providing real-time, continuous data on tissue oxygen levels, Profusa addresses critical gaps in clinical diagnostics and patient care. The company serves a diverse ecosystem of healthcare providers and research institutions, positioning itself as a pivotal player in the burgeoning market for wearable and implantable biochemical monitoring solutions.
How much funding has Profusa raised?
Profusa has raised a total of $184.7M across 9 funding rounds:
Debt
$1.2M
Private Equity
$2.8M
Series A
$2.8M
Private Equity
$11.3M
Series B
$13.2M
Grant
$7.5M
Series C
$45M
Debt
$1M
Stock/Share Issuance
$100M
Debt (2011): $1.2M, investors not publicly disclosed
Private Equity (2013): $2.8M, investors not publicly disclosed
Series A (2013): $2.8M, investors not publicly disclosed
Private Equity (2015): $11.3M, investors not publicly disclosed
Series B (2015): $13.2M backed by Qihoo 360 and Asset Management Ventures
Grant (2016): $7.5M with participation from Defense Advanced Research Projects Agency
Series C (2018): $45M led by VMS Asset Management, Maxim Integrated Ventures, 3E Bioventures Capital, Tasly Pharmaceutical Group, and Atinum Investment
Debt (2020): $1M supported by PPP
Stock/Share Issuance (2025): $100M featuring Ascent Partners
Key Investors in Profusa
Ascent Partners
Ascent Partners Pty Ltd specializes in business sales, acquisitions, and detailed valuations, leveraging extensive industry networks to facilitate high-stakes transactions.
VMS Asset Management
VMS Investment Group is a Hong Kong-based private equity firm providing venture capital, securities-brokerage, and corporate-advisory services.
3E Bioventures Capital
3E Bioventures is a science-driven investment firm that partners with research institutions to advance medical products with strong unmet needs.
What's next for Profusa?
With the successful closure of this major strategic investment, Profusa is poised to transition into a phase of rapid market expansion and operational scaling. The company's strategic roadmap likely includes deepening its penetration into international markets and enhancing the clinical utility of its sensor suite. As the healthcare industry increasingly shifts toward proactive, data-driven patient management, Profusa's ability to deliver actionable, real-time physiological insights will be central to its long-term growth. Future efforts will likely focus on broadening the application of its platform to monitor additional body chemistries, thereby solidifying its competitive advantage in the medical technology landscape.
See full Profusa company page
